FZATA INC

Halethorpe, MD · Biotech · Private

An oral immunotherapeutic probiotic (Saccharomyces boulardii) engineered to secrete anti-TNF-alpha antibodies for localized intestinal delivery to treat ulcerative colitis

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · fzata.com

Sector: Biotech
Headquarters: Halethorpe, MD
Total capital: $12.7M

Federal grants: $12.7M; 17 awards · 2016–2023; Rank in peer group#190 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 15 pending

Capital timeline

Latest events

Aug 2023Federal grantHealth and Human S · Phase II · A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$923K
Apr 2023Federal grantHealth and Human S · Phase II · Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$951K
Oct 2022Federal grantHealth and Human S · Phase II · A Yeast-based Immunotherapy against Clostridioides difficile infection$907K
Aug 2022Federal grantHealth and Human S · Phase II · A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$988K
May 2022Federal grantHealth and Human S · Phase II · Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$1.8M
Apr 2022Federal grantHealth and Human S · Phase II · Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$855K
Nov 2021Federal grantHealth and Human S · Phase II · A Yeast-based Immunotherapy against Clostridioides difficile infection$933K

Show 10 earlier federal awards

Jul 2021Federal grantHealth and Human S · Phase II · A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$1.0M
Apr 2021Federal grantHealth and Human S · Phase II · Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$252K
Apr 2021Federal grantHealth and Human S · Phase II · A Yeast-based Immunotherapy against Clostridioides difficile infection$2.4M
Mar 2021Federal grantHealth and Human S · Phase II · A Yeast-based Immunotherapy against Clostridioides difficile infection$554K
Jul 2020Federal grantHealth and Human S · Phase II · A Yeast-based Immunotherapy against Clostridioides difficile infection$169K
Jan 2018Federal grantHealth and Human S · Phase I · A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection$169K
Jan 2018Federal grantHealth and Human S · Phase I · A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection$169K
Jan 2018Federal grantHealth and Human S · Phase I · Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease$225K
Jan 2018Federal grantHealth and Human S · Phase I · Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease$225K
Dec 2016Federal grantHealth and Human S · Phase I · A Yeast based Immunotherapy against Clostridium difficile Infection$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#190 · top 37%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 15

Aug 15, 2024PendingGenetically-modified Saccharomyces Yeast Strains As Preventative And Therapeutic AgentsUSPTOApplication 18568774
Jan 11, 2024PendingNeutralized Antibody And Method Of Use ThereofUSPTOApplication 18032657
PendingTreatments For PainUSPTOApplication PCTUS2023082360

Show all 15 patent records

Genetically-modified Saccharomyces Yeast Strains As Preventative And Therapeutic AgentsAug 15, 2024 · Application 18568774Pending
Neutralized Antibody And Method Of Use ThereofJan 11, 2024 · Application 18032657Pending
Treatments For PainApplication PCTUS2023082360Pending
Yeast PlatformApplication 63467484Pending
Treatments For PainApplication 63430337Pending
Genetically-modified Saccharomyces Yeast Strains As Preventative And Therapeutic AgentsApplication PCTUS2022033037Pending
Genetically-modified Saccharomyces Boulardii As Preventative And Therapeutic AgentsApplication 63317385Pending
Genetically-modified Saccharomyces Boulardii As Preventative And Therapeutic AgentsApplication 63299693Pending
Neutralized Antibody And Method Of Use ThereofApplication PCTUS2021055686Pending
Genetically-modified Saccharomyces Boulardii As Preventative And Therapeutic AgentsApplication 63209651Pending
Neutralized Antibody And Method Of Use ThereofApplication 63093884Pending
Humanized Tetra-specific Octavalent Antibody Against Clostridium Difficile Toxin A And BApplication PCTUS2020035925Pending
Yeast PlatformApplication 19485205Pending
Treatments For PainApplication 19135748Pending
Yeast PlatformApplication PCTUS2024030115Pending

Triursus Therapeutics IncorporatedSimilar federal contract value in Biotech · null in contracts
Path BioAnalytics, Inc.Similar federal contract value in Biotech · null in contracts
HEPIONE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Lung Biotechnology PBCSimilar federal contract value in Biotech · null in contracts
VORTEX BIOTECHNOLOGY CORPORATIONSimilar federal contract value in Biotech · null in contracts
Flare TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.